Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice

This study has been completed.
Information provided by Department of Veterans Affairs

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Opiate Dependence
2		Additional conditions recognized in this trial
			Opioid-Related Disorders
3		More general conditions related to this trial
			Disorders of Environmental Origin
			Mental Disorders
			Substance-Related Disorders
4		Interventions listed in this trial
			naloxone
			buprenorphine
5		More general drug interventions related to this trial
			Analgesics
			Analgesics, Opioid
			Central Nervous System Agents
			Central Nervous System Depressants
			Narcotic Antagonists
			Narcotics
			Peripheral Nervous System Agents
			Pharmacologic Actions
			Physiological Effects of Drugs
			Sensory System Agents
			Therapeutic Uses
6		Sponsors listed in this trial
			Department of Veterans Affairs
			National Institute on Drug Abuse (NIDA)
			Reckitt and Colman